Groups by Clinical Trial

131I-8H9

Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum Phase 1. April 6, 2010. Recruiting.

Taylor, Xander

Wheeler, Rory Blessed Assurance

17-AAG

17-AAG - Phase 1 April 2006. This study is no longer recruiting patients.

Wilson, Michael

A1G4

A1G4 - Dr. Cheung and Dr. Kushner, Memorial Sloan Kettering, New York City 2005. Not Recruiting.

Luder, Kristen
Wilson, Derek

AMG 479

Protocol No. VICCPHI0542 Principal Investigator Puzanov, Igor Phase Phase I Age Group Adult Scope National Secondary Protocol No. 20050118 Title A Phase I, Open-Label, Dose Finding Study Evaluating the Safety and Pharmacokinetics of AMG 479 in Subjects with Advanced Solid Tumors Objective The purpose of this study is to determine the best and safest dose of AMG 479 and how often it should be taken. Treatment This study involves the drug AMG 479. Description Patients are being asked to take part in this study because they have advanced cancer for which there is no known effective treatment or prior treatment is no longer working for the patient. This study will be using the drug AMG 479 - which is an investigational drug (meaning not approved by the Food and Drug Administration). AMG 479 is a monoclonal antibody. Monoclonal antibodies can locate and bind to cells wherever they are in the body. Many monoclonal antibodies are used in finding or treating cancer cells. The study drug blocks the interaction of insulin like growth factors with their receptor (the insulin like growth factor type 1 receptor). AMG 479 has been shown to stop the growth of cancer cells in several laboratory tests. This is the first time that AMG 479 has been given to humans.

The purpose of this study is to test the safety of AMG 479, how it is processed in the body, and to see if there is an effect on the patient's cancer. This study involves two parts. In Part One, called dose escalation, the purpose is to test the safety of AMG 479 at different doses. It is expected that 3 subjects will be in each group for each dose tested. In Part Two, called dose expansion, patients will be given one of the two highest doses from Part One that also were found to be safe. The purpose is to see what effects (good or bad) these doses of AMG 479 have on the patient and their cancer, and to learn more about how it works in the body. If a patient is eligible and participates, there is a 100% chance that they will receive AMG 479.

About 50 patients total will take part in this study, about 25 here at Vanderbilt.

Applicable Disease Sites Phase I

Therapies Mol. targeted/Immunotherapy/Biologics Drugs AMG 479 Status Open

Eligibility Document PHI 0542 Eligibility 19DEC06.htm

Bender, Michael

Byrd, David

AMG 706

AMG 706 - Phase 1 at M.D. Anderson. No longer recruiting. June 2006.

Cloer, Rebecca

Apomab

A Phase I Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Apomab Administered Intravenously to Subjects with Advanced or Metastatic Solid Malignancies, or Non-Hodgkin's Lymphoma

Cloer, Rebecca

Continuous Hyperthermic Peritoneal Perfusion

Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Abdominal Cancer

Knowles,Raymond

Decitabine

Decitabine (Phase II Cinical Trial at M.D. Anderson (Houston, Tx.)

Wilson, Derek

ET-743 Yondelis

ET-743 (Yondelis)- (Ecteinascidia turbinata) - Sea Squirts - This study is currently recruiting patients

Byrd, David
Wilson, Derek

FR901228 Romidepsin

FR901228 in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma - Single Agent Depsipeptide - This study is currently recruiting patients. Verified by National Cancer Institute (NCI) March 2007

Ixabepilone

Ixabepilone in Treating Young Patients With Refractory Solid Tumors - This study is currently recruiting patients. Verified by National Cancer Institute (NCI) June 2007

Perifosine

Byrd, David

Renamed Deforolimus (Rapamycin AP23573)

Deforolimus AP23573 - Phase I. Put on fast tract for soft tissue and bone sarcoma

Bidleman, Shawn
Cloer, Rebecca
Daunoras, Jay

Sorafenib

[1] Sorafenib in Treating Patients With Soft Tissue Sarcomas - Phase II. November 2006.

Byrd, David

Sutent (sunitinib malate)

Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas

Fish, Jason

Robertson, Nathan

Xeloda

Cloer, Rebecca

Links

See More Clinical Trials

DSRCT References

Contact: dsrct.wiki@gmail.com

[BACK]